发起人
疾病
生物
遗传增强
帕金森病
基因
多巴胺
神经科学
遗传学
医学
基因表达
病理
作者
Erika Elgstrand Wettergren,Fredrik Gussing,Luís Quintino,Cecilia Lundberg
标识
DOI:10.1016/j.neulet.2012.09.059
摘要
Gene therapy is a promising therapeutic tool for Parkinson's disease (PD), but there is a lack of evaluated cell specific promoters that are relevant for the disease. We have chosen PD relevant promoter candidates for gene therapy vectors based on either previous studies; Drd1a, Drd2 and pDyn, or from a microarray study on parkinsonian patients; ACE, DNAJC3, GALNS, MAP1a and RNF25. These candidates have been evaluated in rat striatum to determine their suitability for use in cell specific vectors. The promoters had a neuronal specificity of 91–100%. The efficiency of the promoters was variable, but RNF25, DNAJC3 and MAP1a were comparable to widely used ubiquitous promoters. MAP1a was also affected by dopamine depletion.
科研通智能强力驱动
Strongly Powered by AbleSci AI